Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.

Abstract excerpt

Mutations in RAS oncogenes are frequently observed in human cancers, and the mutations result in activation of the RAS-RAF-MEK-ERK pathway, leading to cell proliferation and survival. The pathway is, therefore, a potent therapeutic target in the RAS-mutant cancers. MEK inhibitors can specifically block the pathway and are one of the key types of drugs for the treatment of the RAS-mutant cancers. As RAS proteins...

Topics

• Humans
• MAP Kinase Kinase Kinases
• Molecular Targeted Therapy
• Mutation
• Neoplasms
• Prognosis
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins
• Proto-Oncogene Proteins p21(ras)
• Signal Transduction